RHEUMATOID ARTHRITIS
Conditions
Interventions
Trade Name: Persantin 100 mg and
Prednisolone 1 mg BP
Product Name: N/A
Product Code: CRx-102
Pharmaceutical Form: Tablet
INN or Proposed INN: prednisolone & dipyridamole
CAS Number: N/A
Current Spon
Sponsors
CombinatoRx, Inc
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: •Subject must be at least 18 years of age. •Have rheumatoid arthritis. •Have at least 3 swollen joints (max = 28) and 3 tender joints (max = 28). •Subject must have baseline C-reactive protein levels of at least 2.2 mg/L and a DAS28 score greater than 4.5. •Subject must have been on DMARD therapy for at least 3 months and be on a stable dose of DMARD therapy for at least 28 days prior to enrollment. •Subject must have voluntarily signed the informed consent Are the trial subjects under 18? Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: •Female subject is pregnant or lactating or of child bearing potential not using acceptable methods of birth control (barriers or abstinence). Female subjects using hormonal birth control are not to be enrolled. •Subject is currently taking any steroids (glucocorticoids). All glucocorticoids must be discontinued for at least one month prior to entering study. Intraarticular, intramuscular, or intravenous glucocorticoids must not have been given at least 6 weeks prior to entering the study. •Subject is currently taking more than 81 mg of aspirin daily. •Subject is currently taking a statin, unless she/he has been on a stable dose of the same statin for at least 3 months prior to entering into the trial. •Subject has any active infections or recent surgical procedures within 30 days of study initiation. •Subject has uncontrolled diabetes mellitus as defined by a HbA1C value = 7.0%. •Subject knowingly has HIV or Hepatitis. •Subject has undergone administration of any investigational drug within 30 days of study initiation. •Subject has a history of hypersensitivity to steroids and/or dipyridamole. •Subject has limited mental capacity or language skills such that simple instructions cannot be followed or information regarding adverse events cannot be provided.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary end point(s): Compare the reduction in CRP levels between subjects treated with CRx-102 plus DMARD therapy and subjects treated with placebo plus DMARD therapy. ;Main Objective: •Compare the response of CRx-102 plus DMARD therapy to placebo plus DMARD therapy in lowering CRP levels in rheumatoid arthritis subjects.;Secondary Objective: •Evaluate the changes in inflammatory cytokines in subjects treated with CRx-102 plus DMARD therapy to placebo plus DMARD therapy. •Evaluate the efficacy of CRx-102 plus DMARD therapy to placebo plus DMARD therapy using ACR-20 and DAS28 indices as well as fatigue scales. | — |
Countries
Estonia
Outcome results
None listed